Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease ... Emmaus Medical, and Vertex Pharmaceuticals. Co-authors also reported multiple relationships with industry.

The Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has announced the ...

Gene therapy, which promises a possible cure for rare diseases like sickle cell, is losing early investors to higher-reward ...

In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals ... decision has ushered in a new era for sickle cell disease treatment — and marked the ...

sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated ... and is also developing therapies for sickle cell disease, type 1 diabetes, and other conditions.

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX Stock Outperforms Industry Image Source: Zacks Investment Research The ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

December 8, 2023 Vertex/CRISPR price sickle cell disease gene therapy at $2.2 mln Vertex Pharmaceuticals and its partner CRISPR Therapeutics said on Friday their sickle cell disease gene therapy ...